Fred Alger Management’s Trevi Therapeutics TRVI Stock Holding History

Fred Alger Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-157,980	Closed	-$1.98M	–	513
2025 Q4	$1.98M	Sell	157,980 -33,065	-17%	-$382K	0.01%	315
2025 Q3	$1.75M	Buy	191,045 +131,620	+221%	+$987K	0.01%	330
2025 Q2	$325K	Sell	59,425 -17,274	-23%	-$107K	﹤0.01%	398
2025 Q1	$482K	Buy	+76,699	New	+$366K	﹤0.01%	366
2024 Q4	–	Sell	-76,544	Closed	-$256K	–	474
2024 Q3	$256K	Buy	+76,544	New	+$228K	﹤0.01%	398

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Fred Alger Management's TRVI Position: Q1 2026 in Review

Fred Alger Management sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 157,980 shares — an estimated $1.98M sold.

Fred Alger Management first reported a position in TRVI in Q3 2024 and held it in 5 quarters. The position peaked at $1.98M in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Fred Alger Management reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
Fred Alger Management sold 157,980 Trevi Therapeutics shares in Q1 2026, an estimated $1.98M.
Fred Alger Management first reported a position in Trevi Therapeutics in Q3 2024 and held it in 5 quarters.
Fred Alger Management's Trevi Therapeutics position peaked at $1.98M in Q4 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.